Tampere, Finland

Visa Kaivosoja

This inventor holds 1 USPTO granted patent. Top assignee: Modulight Corporation. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Visa Kaivosoja

Introduction

Visa Kaivosoja is a notable inventor based in Tampere, Finland. He has made significant contributions to the field of laser technology, particularly in the area of drug delivery systems. His innovative approach combines therapeutic and diagnostic capabilities, showcasing the potential of light-activated solutions in medicine.

Latest Patents

Visa Kaivosoja holds a patent for a theranostic laser system. This system is designed for light-activated drug delivery and monitoring. It includes a light source, a light receiver, and a coupler that allows for the simultaneous coupling of an optical delivery fiber to the light source. This setup enables the transmission of downstream light signals from the light source to the delivery fiber, as well as upstream signals from the fiber to the light receiver. His work in this area represents a significant advancement in medical technology.

Career Highlights

Visa Kaivosoja is currently associated with Modulight Corporation, where he continues to develop innovative solutions in laser technology. His expertise and dedication to research have positioned him as a key figure in the advancement of theranostic systems.

Collaborations

Visa collaborates with talented professionals such as Petteri Uusimaa and Lasse Orsila. Their combined efforts contribute to the ongoing development of cutting-edge technologies in the field.

Conclusion

Visa Kaivosoja's work exemplifies the intersection of innovation and healthcare, particularly through his patented theranostic laser system. His contributions are paving the way for future advancements in medical technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…